E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hormone refractory prostate cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10062904 |
E.1.2 | Term | Hormone-refractory prostate cancer |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the rate of prostate specific antigen (PSA) response (≥ 50% decline in PSA). |
|
E.2.2 | Secondary objectives of the trial |
- To assess safety. - To determine time to PSA progression. - To determine durationof PSA response. - To determine tumour response as per response evaluation criteria in solid tumours (RECIST) criteria. - To determine overall survival. - To assess pharmacokinetics of DTS-201. - To assess CD10 & TOP expression.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male patients ≥18 years. 2. Performance status Karnofsy ≥ 70%. 3. Life expectancy > 3 months. 4. Histologically documented adenocarcinoma of the prostate. 5. Patient with one prior line of chemotherapy only. 6. Patients should have documented progression of disease. Disease progression should meet at least one of the following criteria: a. Prostate spectific antigen (PSA) evidence of progressive prostate cancer during or within 60 days of cessation of first-line chemotherapy consists of a PSA level ≥ 5 ng/ml that has risen on ≥ successive occasions ≥ 2 weeks apart. b. Progression of measurable disease as defined by response evaluation creiteria in solid tumours (RECIST) (confer Appendix 3 of the protocol). c. Progression of bone disease characterized by appearance of one or more new bone lesions. 7. Adequate castration (testosterone levels ≤ 50 ng/dL) by orchiectomy or by luteinising-hormone releasing hormone (LHRH agonist). 8. Patients receiving bisphosphate therapy must be on stable doses with stable symptoms prior to enrolment. 9. Adequate hematological and biological functions: • Bone marrow function: Neutrophils ≥ 1500/mm3, hemoglobin ≥ 10g/dl, platelets ≥ 100 000/mm3. • Hepatic function: Bilirubin < 1.5 upper limit of normal (ULN). Alkaline phosphatase (AP) ≤ 1.5 ULN, (or AP ≤ 5 ULN for patients with bone metastasis). Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 1.5 ULN (or AST/ALT ≤ 3 ULN for patients with liver metastasis). • Renal function: normal with creatinine clearance ≥ 60 ml/min. 10. Normal cardiac function at clinical examination and left ventricular ejection fraction(LVEF) ≥ 50% (according to multiple gated acquisition scan [MUGA] scan or echography). No history of myocardial infarction within last 12 months. 11. Signed informed consent obtained prior to initiation of any study-specific procedures and treatment. 12. Able to adhere to the study visit schedule and other protocol requirements. 13. To be affiliated to or benefit from a social security system if applicable.
|
|
E.4 | Principal exclusion criteria |
1. Previous treatment with an anthracycline or mithoxantrone. 2. Radiotherapy or radioisotope therapy within 4 weeks prior to study drug treatment. 3. Anticancer therapy (chemotherapy, hormone therapy, immunotherapy or biological therapy response modifiers) within 4 weeks prior to study drug first dosing. 4. Steroid therapy within 4 weeks prior to study drug first dosing. 5. Multivitamins, Vitamin D, Calcitrol, and other alternative and food supplement must be discontinued before study registration. 6. Symptomatic brain metastasis per leptomenigeal metastasis or evidence of cord spinal compression. 7. Prior radiotherapy to more than 30% of the bone marrow. 8. Uncontrolled hypercalcemia. 9. History of other malignancies within 5 years at screening, except for adequately treated basal or squamous cell skin cancer. 10. Presence of any serious concomitant systemic disorders incompatible with the study (e.g. active infection). 11. Known positive status for human immunodeficiency virus (HIV) and/or active Hepatitis B or C. 12. Less than 4 weeks after participation to another trial. 13. Any other reason suspected by the investigator as incompatible with study participation.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint of trial is the overall tumour response based on total serum PSA value. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as 6 months after the end of treatment visit (protocol 6.4) of the last patient.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |